Use of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-Hodgkin' s lymphomas

Details for Australian Patent Application No. 2009228616 (hide)

Owner Roche Glycart AG

Inventors Umana, Pablo; Dumontet, Charles; Klein, Christian; Friess, Thomas; Herting, Frank

Agent Davies Collison Cave

Pub. Number AU-A-2009228616

PCT Pub. Number WO2009/118142

Priority 08005554.4 25.03.08 EP; 08007172.3 11.04.08 EP

Filing date 23 March 2009

Wipo publication date 1 October 2009

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

2 September 2010 PCT application entered the National Phase

  PCT publication WO2009/118142 Priority application(s): WO2009/118142

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009228619-Method and device for monitoring a vascular access and extracorporeal blood treatment device comprising a device for monitoring a vascular access

2009228611-Use of Cathepsin C